Table 3.
Up to Date 15 Biosimilars Have Been Approved by the FDA for Rheumatic Diseases
| Comercial Name | Compound Name | Date Aproved | Reference Product |
|---|---|---|---|
| Iabni | Rituximab-arx | December 2020 | Rituxan(rituximab) |
| Hulio | Adalimumab-fkjp | July 2020 | Humira (adalimumab) |
| Avsola | Infliximab-axxq | December 2019 | Remicade(infliximab) |
| Abrilada | Adalimumab-afzb | November 2019 | Humira (adalimumab) |
| Hadlima | Adalimumab-bwwd | July 2019 | Humira (adalimumab) |
| Ruxience | Rituximab-pvvr | July 2019 | Rituxan (rituximab) |
| Eticovo | Etanecerpt-ykro | April 2019 | Enbrel (etanecerpt) |
| Truxima | Rituximab-abbs | November 2018 | Rituxan (rituximab) |
| Hyrimoz | Adalimumab-adaz | October 2018 | Humira (adalimumab) |
| Ixifi | Infliximab-qbtx | December 2017 | Remicade (infliximab) |
| Cyltezo | Adalimumab-adbm | December2017 | Humira (adalimumab) |
| Renflexis | Infliximab-abda | Mayo2017 | Remicade (infliximab) |
| Amjevita | Adalimumab-atto | September 2016 | Humira (adalimumab) |
| Erelzi | Etanecerpt-szzi | August 2016 | Enbrel (etanecerpt) |
| Inflectra | Infliximab-dyyb | April 2016 | Remicade (infliximab) |